JP2016034978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016034978A5 JP2016034978A5 JP2015236260A JP2015236260A JP2016034978A5 JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5 JP 2015236260 A JP2015236260 A JP 2015236260A JP 2015236260 A JP2015236260 A JP 2015236260A JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eculizumab
- pnh
- treatment
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78307006P | 2006-03-15 | 2006-03-15 | |
| US60/783,070 | 2006-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Division JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Division JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016034978A JP2016034978A (ja) | 2016-03-17 |
| JP2016034978A5 true JP2016034978A5 (https=) | 2016-09-23 |
| JP6224059B2 JP6224059B2 (ja) | 2017-11-01 |
Family
ID=38222520
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US20090220508A1 (https=) |
| EP (5) | EP2001490A1 (https=) |
| JP (9) | JP2009530299A (https=) |
| KR (2) | KR20140057635A (https=) |
| AU (1) | AU2007225044C1 (https=) |
| BR (2) | BRPI0708909B8 (https=) |
| CA (2) | CA3022097C (https=) |
| DK (1) | DK2359834T5 (https=) |
| ES (2) | ES2612118T3 (https=) |
| HU (2) | HUE030105T2 (https=) |
| IL (4) | IL302157A (https=) |
| MX (2) | MX340784B (https=) |
| PL (2) | PL3167888T3 (https=) |
| PT (1) | PT2359834T (https=) |
| SI (1) | SI2359834T1 (https=) |
| WO (1) | WO2007106585A1 (https=) |
Families Citing this family (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| HRP20150279T1 (hr) * | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2742802C (en) * | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| CA2780153A1 (en) * | 2009-11-09 | 2011-05-12 | Alexion Pharmaceuticals, Inc. | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| EP2673297A2 (en) | 2011-02-11 | 2013-12-18 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| EP3511339B1 (en) * | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| EP2825989A4 (en) * | 2012-03-16 | 2016-01-06 | Alexion Pharma Inc | METHODS OF DISPENSING MEDICATION INHIBITING COMPLEMENT TO PATIENTS RECEIVING COMPLEMENT INHIBITOR |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| EP2978451B1 (en) * | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| BR112016003142A2 (pt) | 2013-08-28 | 2017-10-17 | Swedish Orphan Biovitrum Ab Publ | ligação de polipeptídeos estáveis ao c5 do complemento humano |
| MX367423B (es) | 2013-08-28 | 2019-08-21 | Affibody Ab | Polipeptidos de union a c5. |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3973994A1 (en) | 2014-06-12 | 2022-03-30 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| EP3207058A1 (en) * | 2014-10-15 | 2017-08-23 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| JP6948942B2 (ja) | 2014-10-15 | 2021-10-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用 |
| WO2016061066A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN113956354A (zh) | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| JP7133925B2 (ja) | 2015-03-23 | 2022-09-09 | アレクシオン ファーマシューティカルズ インコーポレイテッド | ウイルス濾過 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| US20190135903A1 (en) * | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| RS61907B1 (sr) | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| SI3280441T1 (sl) | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| HK1252675A1 (zh) | 2015-06-12 | 2019-05-31 | Alector Llc | 抗cd33抗体及其使用方法 |
| AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| KR20180054639A (ko) | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| US20170073399A1 (en) | 2015-09-11 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| US20190330335A1 (en) | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3359566A1 (en) | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| CA3003458A1 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| RU2733720C2 (ru) | 2015-12-16 | 2020-10-06 | Ра Фармасьютикалз, Инк. | Модуляторы активности комплемента |
| JP7339733B2 (ja) | 2016-01-14 | 2023-09-06 | ケモセントリックス，インコーポレイティド | Ｃ３腎症を処置する方法 |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| CN116284392A (zh) | 2016-03-10 | 2023-06-23 | 艾科赛扬制药股份有限公司 | 活化素2型受体结合蛋白及其用途 |
| WO2017185037A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| WO2018075758A1 (en) | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| KR20190093196A (ko) | 2016-12-07 | 2019-08-08 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| CA3044502A1 (en) * | 2016-12-16 | 2018-06-21 | Samsung Bioepis Co., Ltd. | Stable aqueous anti-c5 antibody composition |
| KR102365871B1 (ko) | 2017-01-31 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| EP3625258A1 (en) | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| JP7194698B2 (ja) | 2017-05-22 | 2022-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与 |
| CA3102086A1 (en) | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Single-chain tnf receptor 2 agonist fusion proteins |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| EP3661493A4 (en) * | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| BR112019023789A2 (pt) | 2017-08-03 | 2020-07-28 | Alector Llc | anticorpos anti-cd33 e métodos de uso dos mesmos |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| RS67119B1 (sr) | 2017-11-14 | 2025-09-30 | Arcellx Inc | Polipeptidi koji obuhvataju d domen i njihove upotrebe |
| US12037389B2 (en) | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| CN111683672A (zh) * | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| JP7490565B2 (ja) | 2017-12-29 | 2024-05-27 | アレクトル エルエルシー | 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法 |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| CN119841953A (zh) | 2018-06-08 | 2025-04-18 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| CN112654394B (zh) * | 2018-06-19 | 2025-07-11 | 阿塔盖有限责任公司 | 针对补体成分5的抗体分子和其用途 |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| BR112020026819A2 (pt) | 2018-06-29 | 2021-04-20 | Alector Llc | anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo |
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
| US12258398B2 (en) | 2018-07-27 | 2025-03-25 | Alector Llc | Anti-Siglec-5 antibodies and methods of use thereof |
| MY210523A (en) | 2018-08-01 | 2025-09-29 | Univ Osaka | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| CR20210155A (es) | 2018-08-31 | 2021-05-10 | Alector Llc | Anticuerpos anti-cd33 y métodos para usarlos |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| JP2022535411A (ja) | 2019-06-04 | 2022-08-08 | ラ ファーマシューティカルズ インコーポレイテッド | 補体阻害剤による炎症性疾患治療 |
| EP3983441A1 (en) | 2019-06-11 | 2022-04-20 | Alector LLC | Anti-sortilin antibodies for use in therapy |
| CR20220040A (es) | 2019-07-31 | 2022-03-02 | Hoffmann La Roche | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab |
| KR20240033090A (ko) | 2019-07-31 | 2024-03-12 | 에프. 호프만-라 로슈 아게 | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
| CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
| US20220259305A1 (en) | 2019-08-05 | 2022-08-18 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| CN115003699A (zh) | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| KR20220110827A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체 |
| US20230035072A1 (en) | 2019-12-12 | 2023-02-02 | Alector Llc | Methods of use of anti-cd33 antibodies |
| MX2022007231A (es) | 2019-12-13 | 2022-07-12 | Alector Llc | Anticuerpos anti-mertk y metodos de uso de los mismos. |
| JP7745557B2 (ja) | 2020-02-24 | 2025-09-29 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| CN116075525A (zh) | 2020-03-31 | 2023-05-05 | 艾莱克特有限责任公司 | 抗mertk抗体及其使用方法 |
| IL296992A (en) | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| EP4135837A1 (en) | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| US20230172930A1 (en) | 2020-05-12 | 2023-06-08 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| EP4255930A1 (en) | 2020-12-02 | 2023-10-11 | Alector LLC | Methods of use of anti-sortilin antibodies |
| WO2022197947A1 (en) | 2021-03-18 | 2022-09-22 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
| JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体 |
| WO2022251446A1 (en) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| MA71628A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Anticorps anti-gpnmb et leurs méthodes d'utilisation |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
| WO2025072726A1 (en) | 2023-09-29 | 2025-04-03 | Trex Bio, Inc. | Tnf-alpha variant fusion molecules |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| AU9149791A (en) | 1990-12-06 | 1992-07-08 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO2001058526A2 (en) | 2000-02-10 | 2001-08-16 | Alexion Pharmaceuticals, Inc. | Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| EP2896631A1 (en) | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| ATE320450T1 (de) * | 2000-12-05 | 2006-04-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003009803A2 (en) | 2001-07-26 | 2003-02-06 | Alexion Pharmaceuticals Inc. | Method of improving cognitive function |
| ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| WO2003081206A2 (en) * | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US20040091490A1 (en) | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| CN100481910C (zh) | 2002-12-16 | 2009-04-22 | 皇家飞利浦电子股份有限公司 | 个人视频 |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| MXPA05011486A (es) * | 2003-04-25 | 2006-04-18 | Immunex Corp | Inductores de expresion de proteina recombinante. |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| JP2006526414A (ja) | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 脱免疫化抗ｃｄ３抗体 |
| US20050027166A1 (en) | 2003-06-17 | 2005-02-03 | Shinya Matsumoto | Endoscope system for fluorescent observation |
| AT412877B (de) | 2003-07-01 | 2005-08-25 | Miba Gleitlager Gmbh | Schichtwerkstoff |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| DK1755659T3 (da) | 2004-03-24 | 2012-02-27 | Abbott Biotherapeutics Corp | Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation |
| EP2338511A3 (en) * | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| ZA200709956B (en) | 2005-05-20 | 2009-02-25 | Genentech Inc | Pretreatment of a biological sample from an autoimmune disease subject |
| WO2007002571A2 (en) | 2005-06-23 | 2007-01-04 | Alexion Pharmaceuticals, Inc. | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
| AU2006265936A1 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Llc | An integrated approach for generating multidomain protein therapeutics |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| JP5722524B2 (ja) | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を抑制することによる同種移植片の生存の延長 |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| WO2007130031A1 (en) | 2006-05-01 | 2007-11-15 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
-
2007
- 2007-03-15 US US12/225,040 patent/US20090220508A1/en not_active Abandoned
- 2007-03-15 EP EP07753249A patent/EP2001490A1/en not_active Ceased
- 2007-03-15 ES ES11001632.6T patent/ES2612118T3/es active Active
- 2007-03-15 AU AU2007225044A patent/AU2007225044C1/en active Active
- 2007-03-15 CA CA3022097A patent/CA3022097C/en active Active
- 2007-03-15 WO PCT/US2007/006606 patent/WO2007106585A1/en not_active Ceased
- 2007-03-15 SI SI200731886T patent/SI2359834T1/sl unknown
- 2007-03-15 PL PL16195355.9T patent/PL3167888T3/pl unknown
- 2007-03-15 KR KR1020147008290A patent/KR20140057635A/ko not_active Ceased
- 2007-03-15 EP EP23198329.7A patent/EP4316465A3/en active Pending
- 2007-03-15 HU HUE11001632A patent/HUE030105T2/en unknown
- 2007-03-15 BR BRPI0708909A patent/BRPI0708909B8/pt active IP Right Grant
- 2007-03-15 JP JP2009500498A patent/JP2009530299A/ja not_active Withdrawn
- 2007-03-15 EP EP11001632.6A patent/EP2359834B1/en not_active Revoked
- 2007-03-15 IL IL302157A patent/IL302157A/en unknown
- 2007-03-15 DK DK11001632.6T patent/DK2359834T5/en active
- 2007-03-15 PL PL11001632T patent/PL2359834T3/pl unknown
- 2007-03-15 EP EP16172335.8A patent/EP3124029A1/en not_active Ceased
- 2007-03-15 MX MX2008011735A patent/MX340784B/es active IP Right Grant
- 2007-03-15 PT PT110016326T patent/PT2359834T/pt unknown
- 2007-03-15 ES ES16195355T patent/ES2965283T3/es active Active
- 2007-03-15 CA CA2645810A patent/CA2645810C/en active Active
- 2007-03-15 HU HUE16195355A patent/HUE066795T2/hu unknown
- 2007-03-15 KR KR1020087024657A patent/KR20080110800A/ko not_active Ceased
- 2007-03-15 BR BR122017024057A patent/BR122017024057B8/pt active IP Right Grant
- 2007-03-15 EP EP16195355.9A patent/EP3167888B1/en active Active
-
2008
- 2008-09-11 IL IL194041A patent/IL194041A/en active IP Right Grant
- 2008-09-12 MX MX2022002589A patent/MX2022002589A/es unknown
-
2012
- 2012-03-22 US US13/426,973 patent/US20120237515A1/en not_active Abandoned
-
2013
- 2013-10-23 JP JP2013219882A patent/JP2014015484A/ja not_active Withdrawn
-
2015
- 2015-12-03 JP JP2015236260A patent/JP6224059B2/ja active Active
-
2016
- 2016-05-06 US US15/148,839 patent/US9718880B2/en active Active
- 2016-09-09 US US15/260,888 patent/US9725504B2/en active Active
- 2016-10-03 US US15/284,015 patent/US9732149B2/en active Active
-
2017
- 2017-02-20 JP JP2017028811A patent/JP2017082017A/ja not_active Withdrawn
- 2017-05-14 IL IL252260A patent/IL252260B/en active IP Right Grant
- 2017-07-05 US US15/642,096 patent/US10590189B2/en active Active
-
2018
- 2018-04-08 IL IL258548A patent/IL258548A/en unknown
- 2018-07-25 JP JP2018139327A patent/JP2018165277A/ja not_active Withdrawn
-
2019
- 2019-10-08 JP JP2019185225A patent/JP2020002176A/ja not_active Withdrawn
-
2020
- 2020-01-23 US US16/750,978 patent/US20200392216A1/en not_active Abandoned
- 2020-02-28 US US16/804,567 patent/US10703809B1/en active Active
-
2021
- 2021-02-17 JP JP2021023314A patent/JP2021073319A/ja not_active Withdrawn
-
2022
- 2022-12-28 JP JP2022211659A patent/JP2023026536A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025091052A patent/JP2025120217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034978A5 (https=) | ||
| CY1124675T1 (el) | Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2012255026A5 (https=) | ||
| JP2016518337A5 (https=) | ||
| JP2016508134A5 (https=) | ||
| JP2016539157A5 (https=) | ||
| JP2014221779A5 (https=) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| JP2015057451A5 (https=) | ||
| JP2017506624A5 (https=) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2015525757A5 (https=) | ||
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016523260A5 (https=) | ||
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| JP2017537912A5 (https=) | ||
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| JP2015516419A5 (https=) | ||
| WO2016074641A8 (zh) | Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| JP2014148552A5 (https=) | ||
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции |